drugset
drugset / Trial / NCT07607210

A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction

NCT07607210 ↗

Phase 2 Not yet recruiting 38 enrolled Hebei Medical University Fourth Hospital
NaSingle-groupOpen-labelTreatment

Summary

Evaluating the efficacy and safety of SHR-1701 combined with chemotherapy for the perioperative treatment of locally advanced resectable Siewert type II adenocarcinoma of the esophagogastric junction.

Timeline

Start
2026-06-01
Primary completion
2026-06-01
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Retlirafusp alfa Protein / enzyme biologic 1800 mg Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background S-1 Small molecule 40 mg Oral
Background S-1 Small molecule 50 mg Oral
Background S-1 Small molecule 60 mg Oral

Indications

gastroesophageal junction adenocarcinoma